BioBlast receives notice of patent issuance for new fusion protein-based platform to treat Friedrich’s Ataxia
"This patent covers the significant innovations we have made in the delivery of therapeutic proteins into mitochondria," said Dalia Megiddo, MD, Chief Executive Officer of BioBlast. "We are
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.